Agilent Technologies (A)
(Delayed Data from NYSE)
$136.68 USD
-2.95 (-2.11%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $136.70 +0.02 (0.01%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.68 USD
-2.95 (-2.11%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $136.70 +0.02 (0.01%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
Zacks News
Will Amkor (AMKR) Q2 Earnings Gain From Strong Auto Demand?
by Zacks Equity Research
Healthy growth in the automotive business and acquisition-related benefits are going to drive Amkor's (AMKR) second-quarter results.
Fortive (FTV) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Fortive's (FTV) second-quarter results are likely to benefit from expanding product portfolio and positive contributions from its strategic buyouts.
Mettler-Toledo (MTD) Q2 Earnings: Disappointment in Store?
by Zacks Equity Research
Mettler-Toledo's (MTD) second-quarter results are likely to benefit from robust laboratory business. However, weak product inspection business remains a concern.
What's in Store for Amphenol (APH) This Earnings Season?
by Zacks Equity Research
Amphenol (APH) is expected to benefit from organic and inorganic growth across most of its end markets in second-quarter 2018 results.
What's in the Cards for Waters Corp (WAT) in Q2 Earnings?
by Zacks Equity Research
Waters Corp (WAT) is scheduled to report second-quarter results which are likely to be driven by its strong position in the pharmaceutical market and robust mass spectrometry portfolio.
Agilent Acquires ULTRA Scientific Assets, Expands Portfolio
by Zacks Equity Research
Agilent (A) recently completes the buyout of the business assets of ULTRA Scientific, thereby expanding its already vast product portfolio.
Agilent (A) to Acquire ProZyme, Expand Glycan Market Share
by Zacks Equity Research
Agilent (A) agrees to acquire glycan analysis company ProZyme for an undisclosed amount.
Agilent (A) Opens Logistics Center, Expands China Foothold
by Zacks Equity Research
Agilent (A) opens a new logistics center in Shanghai to ensure timely delivery of its services in the country.
Agilent Technologies (A) Down 4.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Agilent Technologies (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agilent (A) Down 2.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agilent's AATI Acquisition to Strengthen Portfolio, Footprint
by Zacks Equity Research
Agilent (A) is set to acquire AATI, a developer of automated nucleic acid analysis systems using capillary electrophoresis methods, for $250 million.
Agilent (A) Q1 Earnings & Revenues Beat, '18 View Positive
by Zacks Equity Research
Agilent (A) first-quarter fiscal 2018 results benefit from robust top-line growth and improving end-market demand.
Is a Surprise Coming for Agilent Technologies (A) This Earnings Season?
by Zacks Equity Research
Agilent Technologies (A) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Agilent (A) Down 3.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Agilent (A) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Itron Extends SMECO Contract, Offers Outsourced Solution
by Zacks Equity Research
Itron's (ITRI) contract extension with SMECO anticipated to drive bookings growth in the near term.
Itron (ITRI) Q3 Earnings & Revenues Lag on Shipment Delays
by Zacks Equity Research
Itron's (ITRI) top and bottom lines missed the Zacks Consensus Estimate in Q3 on shipment delays. The company updated its full-year 2017 guidance.
Teradyne (TER) in Focus: Stock Moves 7.4% Higher
by Zacks Equity Research
Teradyne (TER) was a big mover last session, as the company saw its shares rise more than 7% on the day.
Will Agilent Technologies (A) Crush Estimates at Its Next Earnings Report?
by Zacks Equity Research
Agilent Technologies (A) has seen a nice short-term history of beating earnings estimates, and looks poised to crush analyst expectations in its next earnings report as well.
Agilent Technologies (A) Up 10.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Agilent Technologies (A) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
How Agilent Technologies (A) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Agilent Technologies (A) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Is Agilent Technologies (A) Stock a Solid Choice Right Now?
by Zacks Equity Research
Agilent Technologies (A) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
Why Agilent Technologies (A) Stock Might be a Great Pick
by Zacks Equity Research
Agilent Technologies (A) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Agilent (A) Up 4.8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
A reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agilent (A) and Transcriptic Partner on Biology Automation
by Zacks Equity Research
Agilent Technologies, Inc. (A) has significantly expanded its product portfolio with its focus on continued innovation and collaborations with growing companies.